Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 11,000,000 shares, a growth of 7.0% from the April 30th total of 10,280,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the short-interest ratio […]
Daré Bioscience (NASDAQ:DARE – Get Rating) and Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Recommendations This is a breakdown of recent recommendations and […]
Mirae Asset Global Investments Co. Ltd. raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 5.3% during the 4th quarter, HoldingsChannel reports. The firm owned 45,179 shares of the company’s stock after acquiring an additional 2,291 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Apellis Pharmaceuticals were worth […]
Tekla Capital Management LLC lowered its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 75.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,426 shares of the company’s stock after selling 199,650 shares during the period. Tekla Capital Management LLC […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) CEO Cedric Francois sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $85.66, for a total value of $2,569,800.00. Following the sale, the chief executive officer now owns 274,655 shares of the […]